Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery: CRISPR Modulation Reagents

Horizon Discovery, a PerkinElmer company, has launched a new family of CRISPR modulation reagents for CRISPR interference, enabling researchers a better understanding of the biological pathways, processes, and pathologies of disease by repressing genes at the transcription level, and leading to new therapies.

The new reagents include what Horizon Discovery said are the first commercially available synthetic single guide RNAs for CRISPRi. Also included is a dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. The new technologies gives researchers the ability to repress genes in almost all cell lines, across any length of time, and at any scale, Horizon Discovery said.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.